ARGX 116

Drug Profile

ARGX 116

Alternative Names: ARGX-116

Latest Information Update: 23 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator argenx
  • Developer argenx; Staten Biotechnology
  • Class Antibodies; Antihyperlipidaemics
  • Mechanism of Action Apolipoprotein C-III inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dyslipidaemias

Most Recent Events

  • 23 Aug 2017 Preclinical trials in Dyslipidaemias in Netherlands (Parenteral), before August 2017
  • 23 Aug 2017 Preclinical trials in Dyslipidaemias in USA (Parenteral), before August 2017
  • 23 Aug 2017 Pharmacodynamics data from a preclinical study in Dyslipidemias released by argenx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top